Disclosures

Personal Commercial (0)
No disclosures on record

Additional Personal Commercial Disclosures for Education Activities (0)
No disclosures on record

Personal Organizational or Other Non-Commercial (0)
No disclosures on record

Clinical Trial Enroller (5)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIDOS AG10-304: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants</td>
<td>Eidos Therapeutics, a BridgeBio company</td>
<td></td>
</tr>
<tr>
<td>Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTribute-CM)</td>
<td>Eidos Therapeutics, a BridgeBio company</td>
<td></td>
</tr>
<tr>
<td>Evolut™ EXPAND TAVR II Pivotal Trial</td>
<td>MEDTRONIC</td>
<td></td>
</tr>
<tr>
<td>ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)</td>
<td>Novo Nordisk A/S</td>
<td></td>
</tr>
<tr>
<td>Global Prevalence of ATTR-CM in Participants With HFpEF</td>
<td>Pfizer</td>
<td></td>
</tr>
</tbody>
</table>

Institutional Financial Decision-Making Role (0)
No disclosures on record

Expert Witness Testimony (0)
No disclosures on record

Agreement

Certified Education Attestation | Signed on 9/30/2022  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/30/2022  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 9/30/2022  
URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 9/30/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.